Anthropic has acquired Coefficient Bio, a discreet biotech AI startup, in a transaction valued at $400 million through a stock deal, as reported by The Information and Eric Newcomer. While sources close to the deal confirmed its completion to TechCrunch, they refrained from disclosing the specific financial terms.
This acquisition underscores Anthropic's continued strategic expansion into the healthcare and life sciences sectors. It follows their October unveiling of Claude for Life Sciences, an innovative tool designed to empower scientific researchers in accelerating discovery processes.
Coefficient Bio was co-founded just eight months prior by Samuel Stanton and Nathan C. Frey, both of whom previously contributed to computational drug discovery efforts at Genentech’s Prescient Design. The startup specialized in leveraging artificial intelligence to significantly improve the efficiency of drug discovery and various other biological research endeavors.
The Coefficient Bio team, comprising approximately 10 individuals, is anticipated to integrate into Anthropic's existing health and life sciences division.
The Editorial Staff at AIChief is a team of professional content writers with extensive experience in AI and marketing. Founded in 2025, AIChief has quickly grown into the largest free AI resource hub in the industry.